Company Description
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases.
The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease.
Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity.
The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS.
CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
| Country | United States |
| IPO Date | Dec 15, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Dr. Pinchas Cohen Dean, M.D., Ph.D. |
Contact Details
Address: 1455 Adams Drive Menlo Park, California United States | |
| Website | https://www.cohbar.com |
Stock Details
| Ticker Symbol | CWBR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001522602 |
| CUSIP Number | 19249J109 |
| ISIN Number | US19249J3077 |
| Employer ID | 26-1299952 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John M. Amatruda M.D., Ph.D. | Co-Founder |
| Dr. Nir Yacov Barzilai M.D. | Founder & Member of Scientific Advisory Board |
| Dr. Pinchas Cohen Dean, M.D., Ph.D. | Founder & Member of Scientific Advisory Board |
| Jordyn Tarazi | Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 27, 2023 | 25-NSE | Filing |
| Nov 27, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 8-K | Current Report |
| Nov 01, 2023 | 8-K | Current Report |
| Oct 25, 2023 | 425 | Filing |
| Oct 25, 2023 | 8-K | Current Report |
| Oct 06, 2023 | 425 | Filing |
| Oct 06, 2023 | 8-K/A | [Amend] Current Report |
| Oct 04, 2023 | 425 | Filing |
| Oct 04, 2023 | 8-K | Current Report |